SpareBank 1 SMN: Nøkkelinformasjon ved kontantutbytte
Utbyttebeløp: 4,40 kroner
På bakgrunn av Finansdepartementets tilrådning:
- 1,30 kroner for utbetaling i april
- Styret gis fullmakt til å betale inntil 3,10 kroner i fjerde kvartal gitt at forholdene tillater det
Annonsert valuta: NOK
Siste dag inklusive: 25. mars 2021
Ex-dato: 26. mars 2021
Eierregisterdato: 29. mars 2021
Betalingsdato: 7. april 2021
Vedtaksdato: 25. mars 2021
Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12
Om GlobeNewswire
GlobeNewswireGlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
ObsEva Announces Year End 2020 Financial Results and Business Update5.3.2021 07:00:00 CET | Press release
-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Phase 2b dose ranging study planned to initiate in Q4:21 based on positive Phase 2a proof of concept- -Actively pursuing new indications and partnerships to maximize value of pipeline candidates- GENEVA, Switzerland and BOSTON, MA – March 5, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the year ended December 31, 2020 and provided a business update. “2020 was a critical year for ObsEva as it marked the beginning of our transformation from a clinical stage company to one preparing for regulatory approvals and commercialization,” said Brian O’Callaghan, CEO of ObsEva. “The clinical and regulatory achievements of 2
Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition5.3.2021 07:00:00 CET | Press release
Systemic sclerosis (SSc) is a rare disease that affects about 2.5 million people worldwide Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung function and can be life-threateningIn a global study, Actemra/RoActemra reduced the rate of progressive loss of lung function in people with SSc-ILD compared to placeboThe U.S. Food and Drug Administration previously granted Priority Review designation to Actemra/RoActemra for the treatment of SSc-ILD Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for
Novartis announces change to the Executive Committee5.3.2021 07:00:00 CET | Press release
Shannon Klinger, Chief Legal Officer, to leave Novartis on March 15, 2021 Thomas Kendris appointed Chief Legal Officer ad interim Basel, March 5, 2021 — Novartis announced today that Shannon Thyme Klinger, Chief Legal Officer, has decided to resign from Novartis and return to the US to take an executive role at a biotechnology company. Ms. Klinger will step down from the Executive Committee of Novartis (ECN), effective March 15, 2021. Thomas N. Kendris, currently Global Head Litigation and US Country President, will be appointed Chief Legal Officer ad interim and attendee to the ECN in this capacity. Novartis has started an executive search process to evaluate internal and external candidates for the role of its Chief Legal Officer. As Global Head of Litigation, Mr. Kendris has been accountable for leading Novartis Group material litigations and investigations globally. In his more than 25 years with Novartis, he was Novartis US Country Head of Legal, and held country-level responsibil
Arcadis reports transactions under its current share buyback program5.3.2021 07:00:00 CET | Press release
5 March 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, has repurchased 121,284 of its own shares in the period from 26 February 2021 up to and including 4 March 2021 at an average price of €28,58. The consideration of this repurchase was €3.5 million. The repurchase is in accordance with the share buyback program to cover existing obligations under employee incentive plans and to cover commitments for stock dividend, as announced on 19 February 2021. The total number of shares repurchased under this program to date is 252,530 shares for a total consideration of €7.2 million. For more detailed information see: https://www.arcadis.com/en/global/investors/share-information/share-buyback-program/ FOR FURTHER INFORMATION PLEASE CONTACT: ARCADIS INVESTOR RELATIONS Jurgen Pullens Mobile: +31 6 51599483 E-mail: jurgen.pullens@arcadis.com ABOUT ARCADIS Arcadis is a leading global Design & Consultancy organization for natural
Figures for 2020 - Substantial jump in profitability and a record-high result5.3.2021 06:00:00 CET | Press release
Steinhausen, March 5, 2021 – Schweiter Technologies posted a record-high result amid challenging market conditions. Despite the COVID-19 pandemic and negative currency effects, the Group posted sales of CHF 1,160.2 million in 2020, which was only slightly lower than the previous year's CHF 1,179.6 million (-2%). In local currencies, sales were +3% higher versus 2019. Group EBITDA improved by a staggering +43% compared with the previous year (+49% in local currencies), reaching a new record high of CHF 175.7 million. The return on net sales rose by close to 5 %-points to 15.1%. EBIT also rose faster than sales to CHF 137.6 million (previous year: CHF 85.2 million), while net income increased to CHF 103.5 million (previous year: CHF 60.0 million). Operating cash flow came to about CHF 158 million, equivalent to a year-on-year increase of more than 51%. Cash and cash equivalents rose to around CHF 164 million following a dividend distribution of approximately CHF 57 million. At the Genera
Savaria (Sweden) completes the Offer to the shareholders in Handicare and extends the acceptance period4.3.2021 23:00:00 CET | Press release
THIS PRESS RELEASE IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND OR THE UNITED STATES OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE AND IN THE OFFER DOCUMENT PUBLISHED ON SAVARIA (SWEDEN)’S WEBSITE (WWW.NORDIC-OFFER.COM). STOCKHOLM, Sweden, March 04, 2021 (GLOBE NEWSWIRE) -- On 27 January 2021, Savaria (Sweden) AB1 (“Savaria (Sweden)”), a company wholly owned by Savaria Corporation2 (“Savaria”), announced a recommended cash offer to the shareholders of Handicare Group AB (“Handicare”) to tender
Savaria (Sweden) fullföljer Erbjudandet till aktieägarna i Handicare och förlänger acceptperioden4.3.2021 23:00:00 CET | Pressemelding
DETTA PRESSMEDDELANDE UTGÖR INTE ETT ERBJUDANDE, VARKEN DIREKT ELLER INDIREKT, I AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SYDAFRIKA ELLER USA, ELLER I NÅGON ANNAN JURISDIKTION DÄR ETT ERBJUDANDE ENLIGT LAGAR OCH REGLER I SÅDAN RELEVANT JURISDIKTION SKULLE VARA FÖRBJUDET ENLIGT TILLÄMPLIG LAG. AKTIEÄGARE SOM INTE ÄR BOSATTA I SVERIGE SOM ÖNSKAR ACCEPTERA ERBJUDANDET (DEFINIERAT NEDAN) MÅSTE GENOMFÖRA NÄRMARE UNDERSÖKNINGAR AVSEENDE TILLÄMPLIG LAGSTIFTNING OCH MÖJLIGA SKATTEKONSEKVENSER. AKTIEÄGARE HÄNVISAS TILL DE ERBJUDANDERESTRIKTIONER SOM FRAMGÅR AV AVSNITTET ”VIKTIG INFORMATION” I SLUTET AV DETTA PRESSMEDDELANDE OCH AV DEN ERBJUDANDEHANDLING SOM HAR PUBLICERATS PÅ SAVARIA (SWEDEN):S HEMSIDA (WWW.NORDIC-OFFER.COM). STOCKHOLM, Sverige, March 04, 2021 (GLOBE NEWSWIRE) -- Den 27 januari 2021 offentliggjorde Savaria (Sweden) AB1 (“Savaria (Sweden)”), ett bolag helägt av Savaria Corporation2 (“Savaria”), ett rekommenderat kontanterbjudande till aktieägarna i Handicare Gr